a bigger push to avoid ORAL diclofenac

July 2013

You'll see a bigger push to avoid ORAL diclofenac.

Think of it as a "three-strikes" NSAID.

Strike one...it increases the risk of cardiac events as much as high-dose celecoxib (Celebrex)...or rofecoxib (Vioxx), which was withdrawn from the market because of its cardiovascular risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Antithrombotics more emphasis on patients with A fib NOT stopping Pradaxa (dabigatran), Xarelto (rivaroxaban), or Eliquis (apixaban)
Men's Health new option for testosterone replacement called Axiron (AXE-er-on), a solution that's applied to the underarms
Bites & Stings The latest Canadian guidelines for preventing insect bites
Practice Pharmacists will get more involved in "transitions of care"
Ophthalmology treatments for open-angle glaucoma
Osteoporosis STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in patients at low fracture risk
Pediatrics Codeine should no longer be used in kids under 12 years old
Respiratory & Allergy Inhaled steroids are in and LONG-acting beta-agonists are out for exercise-induced bronchoconstriction
Ghost Tablets Patients may not believe their drug is working if they see "ghost" tablets in their stool
Women's Health new OTC screening test for vaginal infections called VagiSense
NSAIDs a bigger push to avoid ORAL diclofenac

a bigger push to avoid ORAL diclofenac

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents